

DECLARATION FOR PATENT APPLICATION UNITED STATES OF AMERICA

As a belov	w named inventor(s), I/We h	ereby decla	re that:
	My/Our residence(s) no	st office add	dress(es) and cltizenship(s) are as stated below my name(s).
	Chemical	Derivativ	es and Their Application As Antitelomerase Agent
	and the specification of (check one)	which	is attached hereto (Aventis Docket No.ST01018G1 US CNT) was filed on November 25, 2003 as U.S. Application Number 10/721,210 and was amended on (if applicable). was described and claimed in PCT Int'l Application Number filed on and as amended under PCT Article 19 on (if any).
	I/We hereby state that including the claims as a I/We acknowledge the d be material to patentabili	uty to disclo	reviewed and understand the contents of the above identified specification, any amendment referred to above.
Ø	I/We hereby claim foreign priority benefits under Title 35. United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:		
Foreign Priority:	0201256 Number	France Country	04/February/2002 Day/Month/Year Filed
Foreign Priority	0106909 Number	France Country	28/May/2001 Day/Month/Year Filed
	I/We hereby claim the application(s) listed belo	benefit und w:	er Title 35, United States Code §119(e) of any United States Provisional
	Number	Filing Date	
	I/We hereby claim the application(s) or internati matter of each of the clair provided by the first para information which is mat became available betwee this application.	benefit und onal applica ms of this ap agraph of T erial to pate n the filing d	ter Title 35, United States Code §120 or 365(c) of any United States ition designating the United States listed below and, insofar as the subject application is not disclosed in the prior United States application in the manner itle 35, United States Code §112, I/We acknowledge the duty to disclose antability as defined in Title 37, Code of Federal Regulations §1.56 which late of the prior application and the national or PCT International filing date of
	PCT/FR02/01767 Application Serial No.	May 27, 2 Filing Date	Pending Status (Patented, Pending)
and the like	so made are nunichable by	for an ima	n of my own knowledge are true and that all statements made on information hese statements were made with the knowledge that willful false statements risonment, or both, under Title 18, United States code §1001, and that such of the application or any patent issued thereon.
Inventors(s):			
1. Full name: [Hervé BOUCHARD		2. Full name: Augustin HITTINGER
Signature:	Herré Boucka	id_	Signature: Hugustin Hillman
	meany, 5th, 2004		Date: landungen 5th 2004
Residence: Thi	enship: France		Country of Citizenship: France
	(City and State/City and Coun	ry only)	Residence: Igny/France (City and State/City and Country only)
P. O. Address:	7 allée de la Prévôté		P. O. Address: 11 rue Galliéni
	94320 Thiais (France)		91430 Igny (France)

	4. Full name:
Signature: Datt: Country of Citizenship: Residence: (City and State/City and Country only) P. O. Address:	Date: Country of Citizenship: Residence: (City and State/City and Country only) P. O. Address:
5. Full name:	
	Signature:

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626

Aventis Docket No. ST01018G1 US CNT